一种新型肿瘤标志物CA 15 - 3在乳腺癌中的临床评估；与癌胚抗原的对比研究
[Clinical evaluation of a new tumor marker, CA 15-3, in breast cancer; a comparative study with CEA].
作者信息
Komuro K, Watanabe K, Ishida T, Sakurai M, Amano R, Hagiwara H, Hara Y, Hanzawa T, Itsubo K
出版信息
Gan To Kagaku Ryoho. 1986 Oct;13(11):3145-9.
Recently, a new RIA method has been developed by Centocor Co., utilizing the monoclonal antibody CA 15-3. We performed a clinical trial to evaluate its utility as a tumor marker for breast cancer in comparison with CEA. We set 15 U/ml as the cut-off value of serum CA 15-3 level from results acquired from controls; 10 volunteers and 17 patients with non-malignant diseases. The CA 15-3 positive rate among the cases of primary breast cancer was 13.3%, which was of poor diagnostic value. In the recurrent cases the positive rate of CA 15-3 was 72.0%, which was valuable compared with that of serum CEA, 52.0%. In the cases of primary cancers other than breast cancer, the positive rate of CA 15-3 was 6.9%.
最近，Centocor公司开发了一种利用单克隆抗体CA 15-3的新型放射免疫分析（RIA）方法。我们进行了一项临床试验，以评估其作为乳腺癌肿瘤标志物相对于癌胚抗原（CEA）的效用。根据10名志愿者和17名非恶性疾病患者（作为对照）的结果，我们将血清CA 15-3水平的临界值设定为15 U/ml。原发性乳腺癌病例中CA 15-3的阳性率为13.3%，诊断价值较差。在复发病例中，CA 15-3的阳性率为72.0%，与血清CEA的阳性率52.0%相比，具有一定价值。在非乳腺癌的原发性癌症病例中，CA 15-3的阳性率为6.9%。
Zotero 插件